Form 4: Allogene EVP Sells Shares for Tax Obligations

Allogene Therapeutics' EVP of R&D, Zachary Roberts, sold 26,269 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Zachary Roberts, Executive Vice President of Research & Development at Allogene Therapeutics, Inc. (ALLO), reported a transaction on January 21, 2026.
• Roberts sold 26,269 shares of Allogene common stock at a price of $1.56 per share.
• The sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plan to satisfy tax withholding obligations upon the vesting of restricted stock units.
• This transaction was not a discretionary trade by Mr. Roberts.
• Following the sale, Roberts beneficially owns 616,866 shares of Allogene common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations upon RSU vesting, not a discretionary sale, thus it has a neutral impact on sentiment.

Positives

• Vesting of restricted stock units (RSUs) for EVP of R&D Zachary Roberts, indicating continued compensation and retention within the company.

Negatives

• No discretionary negative actions were reported; the sale was administrative.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a non-discretionary sale for tax purposes, not an indication of management's view on the stock's future performance.
• Employees: Indicates the vesting of equity compensation, which is a positive for employee retention and motivation within the company.

Key Dates

Recommendation

The Form 4 filing details a non-discretionary 'sell to cover' transaction by an executive to satisfy tax obligations upon restricted stock unit vesting. This is a standard administrative event and does not reflect a change in the executive's confidence in the company or its future prospects. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Allogene Therapeutics, ALLO, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, RSU, Tax Withholding, Stock Sale